BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35489749)

  • 1. Prognostic Value of Peritoneal Cancer Index After Complete Cytoreductive Surgery in Advanced Ovarian Cancer.
    Asp M; Malander S; Bengtsson J; Sartor H; Kannisto P
    Anticancer Res; 2022 May; 42(5):2541-2551. PubMed ID: 35489749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and Predictive Value of the Peritoneal Cancer Index in Primary Advanced Epithelial Ovarian Cancer Patients After Complete Cytoreductive Surgery: Study of Tumor Bank Ovarian Cancer.
    Gasimli K; Braicu EI; Richter R; Chekerov R; Sehouli J
    Ann Surg Oncol; 2015 Aug; 22(8):2729-37. PubMed ID: 25672560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of computed tomography in the assessment of tumour extent and the risk of residual disease after upfront surgery in advanced ovarian cancer (AOC).
    Asp M; Malander S; Wallengren NO; Pudaric S; Bengtsson J; Sartor H; Kannisto P
    Arch Gynecol Obstet; 2022 Oct; 306(4):1235-1243. PubMed ID: 35235024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of peritoneal cancer index in primary advanced ovarian cancer.
    Llueca A; Escrig J;
    Eur J Surg Oncol; 2018 Jan; 44(1):163-169. PubMed ID: 29198495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific Regions, Rather than the Entire Peritoneal Carcinosis Index, are Predictive of Complete Resection and Survival in Advanced Epithelial Ovarian Cancer.
    Rosendahl M; Harter P; Bjørn SF; Høgdall C
    Int J Gynecol Cancer; 2018 Feb; 28(2):316-322. PubMed ID: 29324538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiological assessment of Peritoneal Cancer Index on preoperative CT in ovarian cancer is related to surgical outcome and survival.
    Avesani G; Arshad M; Lu H; Fotopoulou C; Cannone F; Melotti R; Aboagye E; Rockall A
    Radiol Med; 2020 Aug; 125(8):770-776. PubMed ID: 32239470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA; Shaalan W; Elemam D; Mansour H; Melis M; Malik E; Soliman AA
    J Gynecol Oncol; 2018 Jul; 29(4):e47. PubMed ID: 29770618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of initial tumor load and intraperitoneal disease dissemination patterns in patients with advanced ovarian cancer undergoing complete cytoreductive surgery.
    Uzan J; Bonsang-Kitzis H; Rossi L; Rance B; Bats AS; Gosset M; Deloménie M; Pujade-Lauraine E; Lécuru F; Ngô C
    Eur J Surg Oncol; 2019 Sep; 45(9):1619-1624. PubMed ID: 31014987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
    Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
    Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiologically enlarged cardiophrenic lymph nodes and CA-125 in relation to diaphragmatic carcinomatosis, surgical outcome, and overall survival in advanced ovarian cancer.
    Plana A; Talo R; Wallengren NO; Pudaric S; Sartor H; Asp M
    Acta Oncol; 2023 May; 62(5):451-457. PubMed ID: 37129994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
    Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
    Angeles MA; Rychlik A; Cabarrou B; Spagnolo E; Guyon F; Pérez-Benavente A; Gil-Moreno A; Siegrist J; Querleu D; Mery E; Gladieff L; Hernández A; Ferron G; Martinez A
    Gynecol Oncol; 2020 Sep; 158(3):614-621. PubMed ID: 32709536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers.
    Di Lorenzo P; Conteduca V; Scarpi E; Adorni M; Multinu F; Garbi A; Betella I; Grassi T; Bianchi T; Di Martino G; Amadori A; Maniglio P; Strada I; Carinelli S; Jaconi M; Aletti G; Zanagnolo V; Maggioni A; Savelli L; De Giorgi U; Landoni F; Colombo N; Fruscio R
    Front Oncol; 2022; 12():970918. PubMed ID: 36237308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of residual disease on overall survival in women with Federation of Gynecology and Obstetrics stage IIIB-IIIC vs stage IV epithelial ovarian cancer after primary surgery.
    Sørensen SM; Schnack TH; Høgdall C
    Acta Obstet Gynecol Scand; 2019 Jan; 98(1):34-43. PubMed ID: 30168853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
    Sioulas VD; Schiavone MB; Kadouri D; Zivanovic O; Roche KL; O'Cearbhaill R; Abu-Rustum NR; Levine DA; Sonoda Y; Gardner GJ; Leitao MM; Chi DS
    Gynecol Oncol; 2017 Apr; 145(1):15-20. PubMed ID: 28238354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor Load Matters - the Peritoneal Cancer Index in Patients With High-grade Serous Ovarian Cancer.
    Egger E; Merker F; Ralser DJ; Condic M; Marinova M; Muders M; Stope M; Mustea A
    Anticancer Res; 2022 Oct; 42(10):4825-4831. PubMed ID: 36192015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
    Coleridge SL; Bryant A; Kehoe S; Morrison J
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of suboptimal cytoreductive surgery in patients with advanced ovarian cancer based on preoperative and intraoperative determination of the peritoneal carcinomatosis index.
    Llueca A; Serra A; Rivadulla I; Gomez L; Escrig J;
    World J Surg Oncol; 2018 Feb; 16(1):37. PubMed ID: 29471831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.